ArticleThe Journal of thoracic and cardiovascular surgery2018
p63 Silencing induces reprogramming of cardiac fibroblasts into cardiomyocyte-like cells.
Article in The Journal of thoracic and cardiovascular surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Administration of a novel reprogramming formula improves cardiac function and decreases cardiac fibrosis in a myocardial infarction model.JTCVS open · 2025Article
- Review
- Direct cardiac reprogramming: A new technology for cardiac repair.Journal of molecular and cellular cardiology · 2023Review
- p63 silencing induces epigenetic modulation to enhance human cardiac fibroblast to cardiomyocyte-like differentiation.Scientific reports · 2022Article
- Hippo Pathway Effector Tead1 Induces Cardiac Fibroblast to Cardiomyocyte Reprogramming.Journal of the American Heart Association · 2021Article
- Fibroblast transition to an endothelial "trans" state improves cell reprogramming efficiency.Scientific reports · 2021Article
- Clinical potential of angiogenic therapy and cellular reprogramming.JTCVS open · 2021Article
- Reprogramming of Non-myocytes into Cardiomyocyte-like Cells: Challenges and Opportunities.Current cardiology reports · 2020Review
- Enhanced Generation of Induced Cardiomyocytes Using a Small-Molecule Cocktail to Overcome Barriers to Cardiac Cellular Reprogramming.Journal of the American Heart Association · 2020Article
- Commentary: Alas, we are not yet zebrafish.The Journal of thoracic and cardiovascular surgery · 2020Article
- Silencing or not silencingJournal of thoracic disease · 2018Article
- Two decades of heart regeneration research: Cardiomyocyte proliferation and beyond.WIREs mechanisms of diseaseReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveReprogramming of fibroblasts into induced cardiomyocytes represents a potential new therapy for heart failure. We hypothesized that inactivation of p63, a p53 gene family member, may help overcome human cell resistance to reprogramming.
methodsp63 Knockout (
resultsFlow cytometry revealed that a significantly greater number of p63
conclusionsDownregulation of p63 facilitates direct cardiac cellular reprogramming and may help overcome the resistance of human cells to reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.